Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 5, 2025
Reporting Period: Event-based report regarding ongoing debt discussions.
Key Financial Metrics
This filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, or total debt balances. The report focuses exclusively on the status of the company's credit facilities.
Material Changes and Events
- Debt Refinancing Status: The company is engaged in ongoing discussions regarding its existing Credit Agreement dated December 22, 2020 (as amended).
- Lenders: The agreement involves Citizens Bank, N.A., Wells Fargo Bank, N.A., and First-Citizens Bank & Trust Company.
- Timeline: Management states the company remains on track to complete the refinancing or repayment of the Credit Agreement during the fourth quarter of 2025.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates confidence in completing the debt restructuring or repayment by the end of the current quarter. No specific financial guidance, risk factors, or unusual items were disclosed in this text.
Investor Verification Checklist
- Verify the final terms and closing date of the refinancing or repayment of the Credit Agreement in Q4 2025.
- Confirm the total outstanding principal and interest obligations under the existing Credit Agreement.
- Monitor subsequent filings for any changes to the timeline or potential default risks if refinancing is delayed.
- Review the company's most recent 10-Q or 10-K for detailed liquidity and cash flow positions not included in this 8-K.